title: Lipiodol accumulation and transarterial chemoembolization efficacy for HCC patients.
abstract: OBJECTIVE
  To elucidate the prognostic factors for hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE).
  
  
  METHODS
  We studied 85 TACE-treated HCC patients, including 117 lesions, who fulfilled the Milan criteria. The area of iodized poppy-seed oil (lipiodol) accumulation on CT immediately after TACE was classified into three groups, by comparing with the area of HCC detected by CT during hepatic arteriography; accumulation surrounding the HCC lesion (group I), accumulation involving the entire area of the HCC lesion (group II), and accumulation that covered a portion of the HCC lesion (group III).
  
  
  RESULTS
  Among 85 patients, the 1- and 2-year disease free survival (DFS) rates were 67% and 50% in group I, 49% and 29% in group II and 29% and 15% in group III. DFS rate was higher in group I than in groups II and III (p=0.016 and p<0.001). Difference in DFS by lipiodol accumulation pattern was evident in patients aged 75 or younger.
  
  
  CONCLUSIONS
  Lipiodol accumulation pattern as evaluated by CT immediately after TACE may be a powerful indicator of the therapeutic efficacy of TACE in HCC patients.
authors.affiliation: Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Ohkawa
authors.forename: Kazuho
authors.initials: K
authors.lastname: Imanaka
authors.forename: Chie
authors.initials: C
authors.lastname: Tamai
authors.forename: Natsuko
authors.initials: N
authors.lastname: Kawada
authors.forename: Kenji
authors.initials: K
authors.lastname: Ikezawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Uehara
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Itou
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Nakanishi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Katayama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D016461:Chemoembolization, Therapeutic; D018572:Disease-Free Survival; D004998:Ethiodized Oil / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D004998:Ethiodized Oil